Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer

被引:2
作者
Peters, Gabrielle W. [1 ]
Talcott, Wesley [1 ]
Peters, Nicholas V. [2 ]
Dhanasopan, Andrew [3 ]
Lacy, Jill [4 ]
Cecchini, Michael [4 ]
Kortmansky, Jeremy [4 ]
Stein, Stacey [4 ]
Lattanzi, Stephen [4 ]
Park, Henry S. [1 ]
Boffa, Daniel [3 ]
Johung, Kimberly L. [1 ]
Jethwa, Krishan R. [5 ]
机构
[1] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT USA
[2] Yale Univ, Dept Gen Surg, Sch Med, New Haven, CT USA
[3] Yale Univ, Dept Thorac Surg, Sch Med, New Haven, CT USA
[4] Yale Univ, Dept Med Oncol, Sch Med, New Haven, CT USA
[5] Mayo Clin, Radiat Oncol, Rochester, MN USA
关键词
Induction chemotherapy; esophageal cancer; gastroesophageal cancer; PHASE-II TRIAL; NEOADJUVANT CHEMORADIOTHERAPY; TREATMENT TIME; PLUS SURGERY; THERAPY; SURVIVAL; IMPACT;
D O I
10.21037/jgo-22-1005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: For patients with operable locally advanced esophageal carcinoma (LA-EC), we hypothesized that pre-operative induction chemotherapy followed by chemoradiotherapy (IC-CRT) would improve progression-free survival (PFS) and overall survival (OS) when compared to chemoradiotherapy (CRT). Methods: This was a single institution retrospective cohort study including patients with LA-EC who received preoperative-intent IC-CRT vs. CRT between 2013-2019. The Kaplan-Meier method was used to estimate OS and PFS. Cox proportional hazards regression was used to assess for variables associated with survival. The impact of treatment group on pathologic response was assessed by chi-square. Results: Ninty-five patients were included for analysis (IC-CRT n=59; CRT n=36) and the median followup was 37.7 months (IQR: 16.8-56.1). There was no difference in median PFS or OS for IC-CRT or CRT, 22 months (95% CI: 12-59) vs. 32 months (95% CI: 10-57) (P=0.64) and 39 months ( 95% CI: 23-not reached) vs. 56.5 months (95% CI: 38-not reached) (P=0.36), respectively. Amongst the subset of patients with adenocarcinoma histology, there was no difference in median PFS or OS, nor was there when analyses were further restricted to those who received >= 3 cycles of induction 5-fluorouracil and platinum, or for those who underwent esophagectomy. Pathologic complete response occurred in 45% vs. 29% (P=0.24) and N-stage regression occurred in 72% vs. 58% (P= 0.28) of patients in the IC- CRT and CRT cohorts, respectively. Distant metastasis occurred in 44% of patients in each treatment cohort. Conclusions: For patients with LA-EC, preoperative-intent IC-CRT was not associated with improved PFS or OS when compared with CRT.
引用
收藏
页码:1181 / +
页数:16
相关论文
共 20 条
[1]   A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer [J].
Ajani, J. A. ;
Xiao, L. ;
Roth, J. A. ;
Hofstetter, W. L. ;
Walsh, G. ;
Komaki, R. ;
Liao, Z. ;
Rice, D. C. ;
Vaporciyan, A. A. ;
Maru, D. M. ;
Lee, J. H. ;
Bhutani, M. S. ;
Eid, A. ;
Yao, J. C. ;
Phan, A. P. ;
Halpin, A. ;
Suzuki, A. ;
Taketa, T. ;
Thall, P. F. ;
Swisher, S. G. .
ANNALS OF ONCOLOGY, 2013, 24 (11) :2844-2849
[2]   Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial [J].
Al-Batran, Salah-Eddin ;
Homann, Nils ;
Pauligk, Claudia ;
Goetze, Thorsten O. ;
Meiler, Johannes ;
Kasper, Stefan ;
Kopp, Hans-Georg ;
Mayer, Frank ;
Haag, Georg Martin ;
Luley, Kim ;
Lindig, Udo ;
Schmiegel, Wolff ;
Pohl, Michael ;
Stoehlmacher, Jan ;
Folprecht, Gunnar ;
Probst, Stephan ;
Prasnikar, Nicole ;
Fischbach, Wolfgang ;
Mahlberg, Rolf ;
Trojan, Joerg ;
Koenigsmann, Michael ;
Martens, Uwe M. ;
Thuss-Patience, Peter ;
Egger, Matthias ;
Block, Andreas ;
Heinemann, Volker ;
Illerhaus, Gerald ;
Moehler, Markus ;
Schenk, Michael ;
Kullmann, Frank ;
Behringer, Dirk M. ;
Heike, Michael ;
Pink, Daniel ;
Teschendorf, Christian ;
Loehr, Carmen ;
Bernhard, Helga ;
Schuch, Gunter ;
Rethwisch, Volker ;
von Weikersthal, Ludwig Fischer ;
Hartmann, Joerg T. ;
Kneba, Michael ;
Daum, Severin ;
Schulmann, Karsten ;
Weniger, Joerg ;
Belle, Sebastian ;
Gaiser, Timo ;
Oduncu, Fuat S. ;
Guentner, Martina ;
Hozaeel, Wael ;
Reichart, Alexander .
LANCET, 2019, 393 (10184) :1948-1957
[3]   Impact of Overall Treatment Time on Survival and Local Control in Patients With Anal Cancer: A Pooled Data Analysis of Radiation Therapy Oncology Group Trials 87-04 and 98-11 [J].
Ben-Josef, Edgar ;
Moughan, Jennifer ;
Ajani, Jaffer A. ;
Flam, Marshall ;
Gunderson, Leonard ;
Pollock, JonDavid ;
Myerson, Robert ;
Anne, Rani ;
Rosenthal, Seth A. ;
Willett, Christopher .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (34) :5061-5066
[4]   Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial [J].
Eyck, Ben M. ;
van Lanschot, J. Jan B. ;
Hulshof, Maarten C. C. M. ;
van der Wilk, Berend J. ;
Shapiro, Joel ;
van Hagen, Pieter ;
Henegouwen, Mark I. van Berge ;
Wijnhoven, Bas P. L. ;
van Laarhoven, Hanneke W. M. ;
Nieuwenhuijzen, Grard A. P. ;
Hospers, Geke A. P. ;
Bonenkamp, Johannes J. ;
Cuesta, Miguel A. ;
Blaisse, Reinoud J. B. ;
Busch, Olivier R. ;
Creemers, Geert-Jan M. ;
Punt, Cornelis J. A. ;
Plukker, John Th M. ;
Verheul, Henk M. W. ;
Bilgen, Ernst J. Spillenaar ;
van der Sangen, Maurice J. C. ;
Rozema, Tom ;
Ten Kate, Fiebo J. W. ;
Beukema, Jannet C. ;
Piet, Anna H. M. ;
van Rij, Caroline M. ;
Reinders, Janny G. ;
Tilanus, Hugo W. ;
Steyerberg, Ewout W. ;
van der Gaast, Ate .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (18) :1995-+
[5]   Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial [J].
Goodman, Karyn A. ;
Ou, Fang-Shu ;
Hall, Nathan C. ;
Bekaii-Saab, Tanios ;
Fruth, Briant ;
Twohy, Erin ;
Meyers, Michael O. ;
Boffa, Daniel J. ;
Mitchell, Kisha ;
Frankel, Wendy L. ;
Niedzwiecki, Donna ;
Noonan, Anne ;
Janjigian, Yelena Y. ;
Thurmes, Paul J. ;
Venook, Alan P. ;
Meyerhardt, Jeffrey A. ;
O'Reilly, Eileen M. ;
Ilson, David H. .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (25) :2803-+
[6]   Initial results of CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer. [J].
Goodman, Karyn A. ;
Niedzwiecki, Donna ;
Hall, Nathan ;
Bekaii-Saab, Tanios S. ;
Ye, Xing ;
Meyers, Michael O. ;
Mitchell-Richards, Kisha ;
Boffa, Daniel J. ;
Frankel, Wendy L. ;
Venook, Alan P. ;
Hochster, Howard S. ;
Crane, Christopher H. ;
O'Reilly, Eileen Mary ;
Ilson, David H. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[7]   Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer [J].
Kelly, Ronan J. ;
Ajani, Jaffer A. ;
Kuzdzal, Jaroslaw ;
Zander, Thomas ;
Van Cutsem, Eric ;
Piessen, Guillaume ;
Mendez, Guillermo ;
Feliciano, Josephine ;
Motoyama, Satoru ;
Lievre, Astrid ;
Uronis, Hope ;
Elimova, Elena ;
Grootscholten, Cecile ;
Geboes, Karen ;
Zafar, Syed ;
Snow, Stephanie ;
Ko, Andrew H. ;
Feeney, Kynan ;
Schenker, Michael ;
Kocon, Piotr ;
Zhang, Jenny ;
Zhu, Lili ;
Lei, Ming ;
Singh, Prianka ;
Kondo, Kaoru ;
Cleary, James M. ;
Moehler, Markus .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (13) :1191-1203
[8]   Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer [J].
Lin, Steven H. ;
Hobbs, Brian P. ;
Verma, Vivek ;
Tidwell, Rebecca S. ;
Smith, Grace L. ;
Lei, Xiudong ;
Corsini, Erin M. ;
Mok, Isabel ;
Wei, Xiong ;
Yao, Luyang ;
Wang, Xin ;
Komaki, Ritsuko U. ;
Chang, Joe Y. ;
Chun, Stephen G. ;
Jeter, Melenda D. ;
Swisher, Stephen G. ;
Ajani, Jaffer A. ;
Blum-Murphy, Mariela ;
Vaporciyan, Ara A. ;
Mehran, Reza J. ;
Koong, Albert C. ;
Gandhi, Saumil J. ;
Hofstetter, Wayne L. ;
Hong, Theodore S. ;
Delaney, Thomas F. ;
Liao, Zhongxing ;
Mohan, Radhe .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (14) :1569-+
[9]  
National Cancer Institute, Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery
[10]  
NCCN, 2021, Esophageal and Esophagogastric Junction Cancers (Version 4.2021)